Tag Archive for: Flindr Therapeutics

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOM Flindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations Lead asset is a […]